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THE OPIOID CRISIS IN THE WORKPLACE:
WHAT EMPLOYERS MUST DO TO ENSURE
ANTI-DISCRIMINATION COMPLIANCE AND
TO SUPPORT THEIR EMPLOYEES
Jamie Campisi*
I. INTRODUCTION
The United States is facing a severe opioid1 crisis with widespread
consequences affecting every segment of the population. According to the
Centers for Disease Control and Prevention, from 1999 to 2016, more than
350,000 people died in the United States from an opioid overdose.2 More
specificially, over 200,000 people died from prescription opioid overdoses
between 1999 and 2017.3 According to the 2016 National Survey on Drug
Use and Health, 11.5 million Americans misused prescription opioids in
2016 alone.4 These statistics reflect just some of the reasons why President
Trump and the United States Department of Health and Human Services
declared the opioid crisis a nationwide public health emergency on October
26, 2017.5
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1
“Opioids are a class of drugs that act in the nervous system to produce feelings of
pleasure and pain relief.” Common examples are heroin and legally prescribed narcotic
medications to manage severe and chronic pain conditions. Opioid Addiction, GENETICS
HOME REFERENCE – U.S. NAT’L LIBRARY OF MED. (Nov. 2017), https://ghr.nlm.nih.gov/cond
ition/opioid-addiction.
2
See Understanding the Epidemic, CTR. FOR DISEASE CONTROL AND PREVENTION
(Aug. 30, 2017), https://www.cdc.gov/drugoverdose/epidemic/index.html.
3
Prescription Opioid Data - Overview, CTR. FOR DISEASE CONTROL AND PREVENTION
(Aug. 30, 2017), https://www.cdc.gov/drugoverdose/data/prescribing/overview.html
[hereinafter Prescription Opioid Data].
4
Rebecca Ahrnsbrak, Jonaki Bose, Sarra L. Hedden, Rachel N. Lipari, & Eunice
Park-Lee, Key Substance Use and Mental Health Indicators in the United States: Results
from the 2016 National Survey on Drug Use and Health fig.27, SUBSTANCE ABUSE AND
MENTAL HEALTH SERV. ADMIN. (2017), https://www.samhsa.gov/data/sites/default/files/NS
DUH-FFR1-2016/NSDUH-FFR1-2016.htm#opioid.
5
The Opioid Crisis, THE WHITE HOUSE, https://www.whitehouse.gov/opioids/ (last
visited Oct. 23, 2019).
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While the effects of this opioid epidemic on individuals and their
families are the predominant focus of media attention,6 the effects of the
opioid crisis on the local workplace and the national economy are also
significant.7 In fact, a 2017 report by the Council of Economic Advisers
(the “CEA”)8 estimated that the opioid crisis reduced workforce
productivity by over $20 billion in 2015.9
Thus, employers are
undoubtedly feeling the impacts of the opioid crisis, and this Comment
urges employers to exercise caution in the policies they adopt in
confronting the crisis.
In the midst of the current opioid epidemic, employers could be
tempted to engage in rigid, inflexible, and even knee-jerk reactions when
they discover that a job applicant or employee is either taking opioid
medication or has a history of opioid misuse or abuse. Given the
declaration of the opioid epidemic as a national public health emergency
and the heightened media attention surrounding opioid use, employers
might wish to immediately take adverse action against such an employee to
insulate themselves from any potential problems arising from the opioid
use. Such short-sighted conduct would actually expose the employer to
considerable legal liability. This Comment aims to help employers
navigate through potential legal pitfalls while attempting to minimize the
effects of the opioid crisis in their own workplace. It also recommends
positive solutions that can aid employers in realizing that goal. This
Comment therefore asserts that employers must be wary of the potential
minefield of taking adverse actions against employees for their past or
present opioid use—barring current illicit use—without legal justification,
and instead, encourages employers to become part of the solution to
combatting this crisis.
Part II of this Comment describes the opioid epidemic’s specific
effects on both the workplace and the U.S. economy, demonstrating its
grave effects in the employment context. Part III discusses how the
6

See, e.g., Erin Schumaker, Here’s How the New Opioid Deal Could Help Kids and
Families, HUFFINGTON POST (Oct. 24, 2018), https://www.huffingtonpost.com/entry/newopioid-deal-kids-families_us_5bbcc11ae4b0876edaa26021.
7
See Dan Mangan, Economic Cost of the Opioid Crisis: $1 Trillion and Growing
Faster, CNBC (Feb. 13, 2018),
https://www.cnbc.com/2018/02/12/economic-cost-of-the-opioid-crisis-1-trillion-andgrowing-faster.html.
8
The CEA is a United States agency within the Executive Office of the President
charged with offering the President objective economic advice on the formulation of both
domestic and international economic policy. Council of Economic Advisers, THE WHITE
HOUSE, https://www.whitehouse.gov/cea/(last visited Sept. 29, 2019).
9
The Underestimated Cost of the Opioid Crisis, THE COUNCIL OF ECON. ADVISERS 1
(Nov. 2017), https://www.whitehouse.gov/sites/whitehouse.gov/files/images/The%20Under
estimated%20Cost%20of%20the%20Opioid%20Crisis.pdf [hereinafter 2017 CEA Report].
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Americans with Disabilities Act (the “ADA”) and state anti-discrimination
laws provide substantial protections to employees who are either past
(illicit or otherwise) or present legal opiate users. It is therefore crucial for
employers to understand which actual or potential employees are covered
under the ADA and their own state’s anti-discrimination laws regarding
opioid use and the legal protections afforded to their employees. Part IV
recommends that employers exercise caution in drafting new drug policies
or confirm that their existing policies are ADA compliant. Part IV also
explains how employers often use their drug policies as justification for
adverse employment actions against employees and how such drug policies
might be significant sources of litigation and legal exposure if not drafted
correctly. For instance, employers must be particularly wary of the “drugfree workplace” label and the drug testing procedures contained in their
policies. Part V encourages employers to take a proactive approach and
recognize the substantial impact they can have in confronting the opioid
epidemic. It makes recommendations to employers regarding possible
support systems to implement, thereby cultivating good will with their
employees and reducing the likelihood that the epidemic’s negative effects
will seep into their workplace. Finally, Part VI provides a brief conclusion
of the Comment’s analysis.
II. EVALUATING THE EFFECTS OF THE OPIOID CRISIS IN THE EMPLOYMENT
CONTEXT
On October 24, 2018, President Trump signed the Substance UseDisorder Prevention that Promotes Opioid Recovery and Treatment for
Patients and Communities Act—also known as the SUPPORT for Patients
and Communities Act (the “Act”)—into law.10 Recognizing the magnitude
of the opioid crisis affecting the country, the final version of this legislation
passed in the Senate with a remarkably bipartisan, 98 to 1, vote on October
3, 2018.11 Apart from “[t]he most high-profile aspects of the bipartisan bill
deal[ing] directly with the [opioids],”12 the Act also includes provisions
discussing the opioid epidemic’s effect on children and families.13 For
example, the Act includes provisions supporting residential treatment
facilities where children can stay with their parents receiving substance use
Marianna Sotomayor, Trump Signs Sweeping Opioid Bill with Vow to End ‘Scourge’
of Drug Addiction, NBC NEWS (Oct. 24, 2018), https://www.nbcnews.com/politics/congress
/trump-signs-sweeping-opioid-bill-vow-end-scourge-drug-addiction-n923976.
11
Colby Itkowitz, Senate Easily Passes Sweeping Opioid Legislation, Sending to
President Trump, WASH. POST (Oct. 3, 2018), https://www.washingtonpost.com/politics/201
8/10/03/senate-is-poised-send-sweeping-opioids-legislation-president-trump/?utm_term=.06
b83d99b5a5.
12
Schumaker, supra note 6.
13
Id.
10
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disorder treatment instead of going into the foster care system and adopts
plans outlining care for infants with neonatal opioid exposure.14 The Act
also includes a section “addressing economic and workforce impacts of the
opioid crisis.”15 Section 8401 outlines a pilot program that authorizes the
Secretary of Labor to make $100 million in grants per fiscal year to state
workforce agencies, which can in turn make subgrants to local workforce
development boards to address the economic and workplace effects of the
opioid crisis.16 Section 8401, however, is just one relatively short section
in an immense piece of legislation and was not included in the mainstream
media’s coverage of the bill’s signing.17 Finding ways to assist individuals
and families struggling with substance use disorder is deservedly at the
forefront of conversations surrounding the opioid epidemic, so it is no
surprise that the epidemic’s effect in the employment arena is not as
frequently considered. The opioid crisis, however, is also having severe
negative impacts on the U.S. economy and the employment sector as a
whole.
According to a report issued by Altarum, a “nonprofit health research
and consulting institute,”18 the opioid epidemic’s economic cost in the U.S.
from 2001 to 2017 exceeded $1 trillion.19 The report also projected that the
opioid crisis would cost the U.S. economy an additional $500 billion by
2020.20 As the CEA described in its November 2017 report, the “nonfatal
costs” of the opioid epidemic, such as healthcare, criminal justice, and
employment costs, are significant.21 For example, in 2013 alone,
prescription opioid abuse resulted in approximately $28 billion in

14

Id.
SUPPORT for Patients and Communities Act, H.R. 6, 115th Cong. § 8041 (2018).
16
Id.
17
See, e.g., John Fritze & David Jackson, What’s Included in the Opioids Bill Signed
by President Trump, USA TODAY (Oct. 24, 2018), https://www.usatoday.com/story/news/po
litics/2018/10/24/donald-trump-opioids-bill-includes-changes-trafficking-treatment/175232
9002/; Sarah Owermohle, Trump to Sign Sweeping Bill, POLITICO (Oct. 24, 2018),
https://www.politico.com/newsletters/politico-pulse/2018/10/24/trump-to-sign-sweepingopioid-bill-386557; Itkowitz, supra note 11; Sotomayor, supra note 10.
18
Economic Toll of Opioid Crisis in U.S. Exceeded $1 Trillion Since 2001, ALTARUM
(Feb. 13, 2018), https://altarum.org/news/economic-toll-opioid-crisis-us-exceeded-1-trillion2001.
19
Id. See also Greg Allen, Cost of U.S. Opioid Epidemic Since 2001 is $1 Trillion and
Climbing, NPR (Feb. 13, 2018), https://www.npr.org/sections/health-shots/2018/02/13/5851
99746/cost-of-u-s-opioid-epidemic-since-2001-is-1-trillion-and-climbing; Tom Valentino,
Opioid Crisis Now $1 Trillion Problem, BEHAV. HEALTHCARE EXECUTIVE EXEC. (Feb. 13,
2018), https://www.behavioral.net/article/prescription-drug-abuse/opioid-crisis-now-1-trillio
n-problem.
20
ALTARAM, supra note 18.
21
See 2017 CEA Report, supra note 9, at 8.
15
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healthcare and substance use disorder treatment costs,22 $7.5 billion in
criminal justice costs,23 and over $20 billion in reduced productivity
costs.24 Critical to note in assessing the opioid epidemic’s costs to
economic productivity is the fact that most deaths resulting from opioid
overdoses in the U.S. in 2015 occurred among individuals ranging between
twenty-five and fifty-five years old—prime working age.25 Given the
unfortunate fact that most of the opioid epidemic fatalities are resulting in
the loss of prime-working-age individuals, it comes as no surprise that the
American labor-force participation rate, which calculates the percentage of
Americans either employed or actively seeking work, hovered between
62.7% and 63.1% in both 201726 and 201827—low by historical standards.28
For example, between 1986 and 2009, the labor force participation rate
consistently fell between 65% and 67%.29 Alan Krueger, a Princeton
economist, has conducted a study showing “a striking relationship between
these missing workers and increasing opioid addiction”30 and has
concluded that “over the past fifteen years, labor-force participation among
prime-age workers has declined the most in U.S. counties where opioid
prescriptions are the most plentiful.”31 While it is difficult to establish
whether the increased rate in opioid prescriptions is causing the lower labor
force numbers or whether the lower labor force numbers are resulting in
increased opioid prescriptions, Krueger explains that “[r]egardless of the
direction of causality, the opioid crisis and depressed labor force
22

Curtis Florence, Feijun Luo, Likang Xu, & Chao Zhou, The Economic Burden of
Prescription Opioid Overdose, Abuse and Dependence in the United States, 2013, NAT’L
CTR. FOR INJURY PREVENTION AND CONTROL, CTR. FOR DISEASE CONTROL AND PREVENTION
1, 13 (Oct. 2016), https://stacks.cdc.gov/view/cdc/55377.
23
Id.
24
Id.
25
See 2017 CEA Report, supra note 9, at 5.
26
Gillian B. White, The Opioid Crisis Comes to the Workplace, THE ATLANTIC (Dec.
21,
2017),
https://www.theatlantic.com/business/archive/2017/12/workers-dyingoverdoses/549008/.
27
United States Labor Force Participation Rate, TRADING ECONOMICS,
https://tradingeconomics.com/united-states/labor-force-participation-rate (click calendar
visual beneath the chart and insert “2018-01-01” and “2018-12-31” to view 2018 labor force
participation rate data) (last visited Sept. 29, 2019).
28
See White, supra note 26; see U.S. DEP’T OF LABOR, BUREAU OF LABOR STATISTICS,
CIVILIAN LABOR FORCE PARTICIPATION RATE, https://www.bls.gov/charts/employmentsituation/civilian-labor-force-participation-rate.htm (last visited Sept. 10, 2019).
29
Id.
30
See White, supra note 26.
31
Id. See also Alan B. Krueger, Where Have All the Workers Gone? An Inquiry Into
the Decline of the U.S. Labor Force Participation Rate, BROOKINGS 48–49 (Sept. 7, 2017)
https://www.brookings.edu/bpea-articles/where-have-all-the-workers-gone-an-inquiry-intothe-decline-of-the-u-s-labor-force-participation-rate/ (analyzing the growth of opiod
prescription use as a factor in the decrease of labor force participation).
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participation are now intertwined in many parts of the United States.”32
Additionally, employers not only face a reduced labor force, but face
opiate-related issues with their existing employees as well. According to a
2017 National Safety Council survey, 70% of employers with fifty or more
employees have experienced workplace incidents due to prescription drug
use.33 More specifically, 39% of those employers cited that they have dealt
with employee absenteeism and 29% claimed to have experienced
employees’ impaired or decreased job performance because of prescription
drug use.34 Succinctly stated, employers are dealing with real challenges to
the national workforce and economy, in addition to direct effects within
their own workplaces, because of the current opioid crisis.
III. ANTI-DISCRIMINATION PROTECTIONS OFFERED BY THE AMERICAN
WITH DISABILITIES ACT
Employers experiencing the direct effects of the current opioid
epidemic must be aware of how to properly treat opioid-using employees
and how to recognize, evaluate, or characterize misuse and abuse.
Employers unsure of how to deal with the opioid epidemic might be
tempted to draft blanket policies forbidding all opiate use, thereby failing
to distinguish between an employee’s legal use and abuse. Part IV
describes some cases in which employers have utilized and attempted to
enforce such blanket policies, ultimately exposing themselves to litigation
that could have been avoided had they remained ADA-compliant. It is true
that “[h]istorically, an employee’s drug use in violation of a ‘drug free
workplace’ policy almost surely meant termination,”35 but that no longer
remains the case today. Ultimately, employers considering taking adverse
employment action against an opioid-using employee must be careful to
ensure that they are not punishing legal opiate use (such as employees
taking opioid medications to treat “moderate-to-severe pain, after surgery
or injury, or pain from health conditions like cancer”)36 and that the
employee is not a member of a protected class under the ADA and/or their
own state’s anti-discrimination laws. It is therefore critical for employers
to have a firm grasp on the employee protections afforded to opioid users
under both the ADA and existing state law. This section will explain who
32

See Krueger, supra note 31, at 55.
How the Prescription Drug Crisis is Impacting American Employers, NAT’L SAFETY
COUNCIL 1, 6, 8 (2017), https://www.nsc.org/Portals/0/Documents/NewsDocuments/2017/M
edia-Briefing-National-Employer-Drug-Survey-Results.pdf [hereinafter 2017 NSC Report].
34
Id. at 8.
35
Benjamin E. Widener, Opioid Accommodation: Overview, Case Study and
Recommendations, N.J.L.J. (Aug. 10, 2018, 10:00 AM), https://www.law.com/njlawjournal/
2018/08/10/opioid-accommodation-overview-case-study-and-recommendations/.
36
See Prescription Opioid Data, supra note 3.
33
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qualifies as a disabled individual entitled to ADA protections and what
protections the ADA offers to those individuals. It will then apply both of
those concepts more narrowly to the opioid use context.
A. An Introduction to the American with Disabilities Act in the
Employment Context
The ADA was passed by Congress in 1990 “to provide a clear and
comprehensive national mandate for the elimination of discrimination
against individuals with disabilities; [and] to provide clear, strong,
consistent, enforceable standards addressing discrimination against
individuals with disabilities.”37 The ADA defines “employers” as persons
engaged in commercial industries with fifteen or more employees.38 It
further mandates that employers “shall [not] discriminate against a
qualified individual on the basis of disability in regard to job application
procedures [or] the hiring, advancement, or discharge of employees . . . .”39
In order to fully understand which employees are protected by this ADA
mandate in the opioid context, it is first necessary to further define
“disability” and “qualified individual[s].”
1. Defining Covered Disabilities
The ADA defines “disability . . . with respect to an individual” as “(i)
[a] physical or mental impairment that substantially limits one or more of
the major life activities of such individual; (ii) [a] record of such
impairment; or (iii) [b]eing regarded as having such impairment.”40 Thus,
employees can qualify as disabled under the ADA through any of the
preceding three definitions—the “actual disability” prong, the “record of”
prong, or the “regarded as” prong.
In the opioid context, the “actual disability” prong could, for example,
include an employee who is suffering from opioid addiction as the result of
taking legally prescribed opiate medications.41 The addiction could be
either the physical and/or mental impairment that substantially limits one or
more of the employee’s major life activities, such as caring for oneself,
communicating, interacting with others, and working.42 A non-addicted
employee taking legally-prescribed opiates could also qualify under the
“actual disability prong” because the underlying medical condition (such as

37
38
39
40
41
42

Americans with Disabilities Act of 1990, 42 U.S.C. § 12101(b)(1)–(2).
42 U.S.C. § 12111(2), (5)(A) (1990).
Id. at § 12112(a).
29 C.F.R. § 1630.2(g)(1)(i)–(iii) (2019).
Id. at § 1630.2(h)(1)–(2).
Id. at § 1630.2(i)(i).

CAMPISI-FORMATTED (DO NOT DELETE)

11/15/2019 7:25 PM

566

[Vol. 50:559

SETON HALL LAW REVIEW

cancer)43 requiring the use of those opiates will typically qualify as the
physical or mental impairment impeding an individual’s major life
activities required to satisfy the ADA’s definition of a disability.44
Moreover, the ADA Amendments Act of 2008 mandates that the definition
of disability is meant to be read broadly45 and instructs that “the question of
whether an individual’s impairment is a disability under the ADA should
not demand extensive analysis.”46 Employers should be aware, therefore,
that it will not be difficult for an employee taking opioid medications to
successfully argue that he or she has an “actual disability.”
The “record of” prong in the opioid context could include an
employee with a record of past drug addiction and/or drug treatment and
rehabilitation programs.47 Assuming the employee has overcome their
addiction and no longer has an “actual disability,” the employee would still
have a record of a physical or mental impairment—the prior addiction—
that substantially limited one or more of their major life activities.48
The ADA deems an employee disabled under the “regarded as” prong,
even if they do not have, or never have had, a physical or mental
impairment that substantially limits one or more of their major life
activities, if the employer perceives them as having such impairment. 49
Thus, an employee could be deemed disabled under the ADA if an
employer regards an employee as being addicted to opioids, regardless of
whether that perception is correct, and regardless of whether that employee
actually uses opiates or not.50
2. Defining Qualified Individuals and Their Rights Under the
ADA
The ADA does not permit employers to discriminate against “a
qualified individual” on the basis of any of the three preceding definitions
of disability. Importantly, a “qualified individual” is someone who can
perform the essential functions of their job, with or without reasonable
accommodation.51 In the opioid context, it is important to note that an
employee or job applicant who is currently engaging in the illegal use of

43

See Prescription Opioid Data, supra note 3.
29 C.F.R. § 1630.2(g)(1)(i).
45
Elisa Y. Lee, Note, An American Way of Life: Prescription Drug Use in the
American Workplace, 45 COLUM. J.L. & SOC. PROBS. 303, 321 (2011).
46
ADA Amendments Act of 2008, 110 P.L. 325, 122 Stat. 3553, § 2(b)(5).
47
29 C.F.R. § 1630.2(k)(1).
48
Id. at §1630.2(k)(2).
49
Id. at § 1630(l)(1).
50
Id.
51
42 U.S.C. § 12111(8) (2018).
44
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drugs is not considered a qualified individual.52 As a result, employers are
free to take adverse employment actions without fear of consequences
stemming from employee’s current illegal drug use.53
Notably, the Equal Employment Opportunity Commission (EEOC)
has defined “current illegal drug” use as having “occurred recently enough
to justify an employer’s reasonable belief that involvement with drugs is an
ongoing problem.”54 Furthermore, an employee who tests positive on a
drug test will also be considered a current illegal drug user.55
On the other hand, the ADA specifies that employees who have
completed a drug rehabilitation program and are no longer using illegal
drugs,56 employees who are currently enrolled in a drug rehabilitation
program but are no longer using illegal drugs,57 and those who are
erroneously regarded as using illegal drugs58 are qualified individuals
entitled to ADA protection. Moreover, qualified individuals include those
taking opioid medications legally prescribed by a healthcare professional.59
If an individual were to become addicted to that opiate prescription
medication while under the doctor’s care, they would still be protected
under the ADA because the use of the prescription drugs as directed is not
illegal.60 Individuals who utilize prescription medications in ways other
than prescribed, however, would be considered engaged in the
aforementioned current illegal use of drugs.61
These definitions of legal and illegal drug use notably leave a lapse in
ADA protection for employees who relapse while receiving treatment.
While “[t]he chronic nature of addiction means that for some people
relapse . . . can be part of the process . . . and relapse doesn’t mean
treatment has failed,”62 the ADA is clear that only those “who have
52

Id. at § 12114(a).
Id.
54
U.S. EQUAL EMP’T OPPORTUNITY COMM’N, EEOC-M1A, A TECHNICAL ASSISTANCE
MANUAL ON THE EMPLOYMENT PROVISIONS (TITLE I) OF THE AMERICANS WITH DISABILITIES
ACT § 8.3 (1992) [hereinafter EEOC MANUAL].
55
Id.
56
42 U.S.C. § 12114(b)(1).
57
Id. at § 12114(b)(2).
58
Id. at § 12114(b)(3). See also 29 CFR § 1630.2(g)(1)(iii).
59
42 U.S.C. § 12111(6)(A).
60
LEGAL ACTION CENTER, Questions and Answers from Webinar: Know Your Rights:
Employment Discrimination Against People with Alcohol/Drug Histories, SUBSTANCE
ABUSE AND MENTAL HEALTH SERV. ADMIN. 2, https://www.samhsa.gov/sites/default/files/pa
rtnersforrecovery/docs/QA_Employment_Discrimination.pdf (last visited September 29,
2019).
61
Id.
62
Drugs, Brains, and Behavior: The Science of Addiction, Treatment and Recovery,
NAT’L INST. ON DRUG ABUSE (July 2018), https://www.drugabuse.gov/publications/drugsbrains-behavior-science-addiction/treatment-recovery [hereinafter Drugs, Brains, and
53
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completed a drug rehabilitation program and are no longer using illegal
drugs”63 or those “who are currently enrolled in a drug rehabilitation
program but are no longer using illegal drugs”64 are entitled to protection.
Thus, even an employee who is actively participating in treatment will be
deemed to have engaged in current illegal drug use if they have a positive
drug test.65 A similarly-situated employee could also be deemed to have
engaged in current illegal drug use if they suffer a relapse that could justify
an employer’s reasonable belief that involvement with drugs is an ongoing
problem.66 Such employer determinations are made on a case-by-case
basis.67
Despite this somewhat expansive definition of “current illegal drug
use,” it should be noted that individuals currently participating in
medication-assisted treatments (MAT) are also qualified individuals subject
to the protections of the ADA.68 MAT utilizes controlled substances such
as methadone and buprenorphine to treat opioid addiction both to shortacting opioids, such as heroin, and synthetic opioids, such as prescription
opiate drugs.69 MAT “normalize[s] brain chemistry, block[s] the euphoric
effects of opioids, relieve[s] psychological cravings, and normalize[s] body
functions,”70 allowing recipients to regain stable physical and
psychological functioning. Thus, although methadone and buprenorphine
are actually opioids,71 MAT patients’ use of those substances is not
considered illegal drug use; rather, it is considered part of a prescribed
course of rehabilitative treatment. By their very participation in MAT,
employees will have a “record of” a disability—their opioid addiction—
and be “regarded as” having that disability.72 As a result, employees
participating in MAT programs are qualified individuals entitled to ADA
protection, as long as they are not also engaging in any current illegal drug
use.
Employers will be considered to have wrongfully discriminated
against a qualified individual employee if they fail to make reasonable
Behavior].
63
42 U.S.C. § 12114(b)(1) (emphasis added).
64
Id. at § 12114(b)(2) (emphasis added).
65
See EEOC MANUAL, supra note 54.
66
Id.
67
Id.
68
U.S. DEP’T OF HEALTH AND HUMAN SERV., SUBSTANCE ABUSE AND MENTAL HEALTH
SERV. ADMIN., authored by LEGAL ACTION CENTER, HHS PUBLICATION NO. (SMA) 09-4449,
KNOW YOUR RIGHTS: RIGHTS FOR INDIVIDUALS ON MEDICATION-ASSISTED TREATMENT 6
(2009) [hereinafter KNOW YOUR RIGHTS].
69
Id. at 3.
70
Id.
71
See Drugs, Brains, and Behavior, supra note 62.
72
See KNOW YOUR RIGHTS, supra note 68, at 6–7.
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accommodations for that employee73 or “deny employment opportunities to
a job applicant or an advancement to a current employee based on the
knowledge that they would have to make a reasonable accommodation for
that employee.”74 Reasonable accommodations can consist of a variety of
measures, such as restructuring some of the employee’s job responsibilities,
permitting flexible work schedules or part-time work, or reassigning the
employee to another vacant position.75 For example, adjusting work hours
to allow an employee no longer engaging in current illegal drug use to seek
treatment and rehabilitative services could constitute a reasonable
accommodation.
3. Concluding Anti-Discrimination Protections
Before taking any adverse employment action against an employee on
the basis of their drug use, employers must protect themselves from
liability by ensuring that the employee is not a qualified individual with a
qualifying disability under the ADA, or, if the employee is a qualified
individual, that the employee could not be afforded a reasonable
accommodation.
Employers should also be aware of the anti-discrimination laws
adopted by their own states. With the exception of Alabama,76 every state
has a general anti-discrimination statute that protects employees from
discrimination on the basis of disability or handicap.77 The majority of
these state laws against discrimination in employment include categories of
employers that are not regulated by the ADA, such as state or public
employers and employers with fewer than fifteen employees.78
B. Options for Employers Wanting to Take Adverse Employment
Action Against a Disabled Employee
While employers must ensure compliance with the ADA and its state
equivalents, they are not without recourse if they wish to take adverse
employment action against an employee with an ADA-recognized
73

42 U.S.C. § 12112(b)(5)(A) (2018).
Id. at § 12112(b)(5)(B).
75
Id. at. § 12111(9)(B).
76
Alabama does not have a general anti-discrimination statute but does require state
and state-funded employers to employ “the blind, the visually handicapped and the
otherwise physically disabled . . . on the same terms and conditions as the able-bodied,
unless it is shown that the particular disability prevents the performance of the work
involved.” ALA. CODE § 21-7-8; State Employment-Related Discrimination Statutes, NAT’L
CONF. OF STATE LEGISLATURES 1 (July 2015), http://www.ncsl.org/documents/employ/Discr
imination-Chart-2015.pdf.
77
State Employment-Related Discrimination Statutes, supra note 76.
78
Id.
74
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disability. Consider the following scenario: A laborer for a twentyemployee construction company is taking opioid medications for acute
chronic back pain. His back pain has led him to request that he only work
three days a week, but his employer needs someone for five days and
cannot afford to bring on an additional employee. The side effects from his
opioid medications inhibit his ability to operate machinery necessary to
perform his job. This section will explain what options the ADA affords
employers in such situations.
It is first necessary to note that employers do not have to make a
reasonable accommodation for a disabled job applicant or employee if they
“can demonstrate that the accommodation would impose an undue hardship
on the operation of the[ir] business.”79 An undue hardship in this context is
defined as an accommodation requiring significant difficulty or expense for
the employer.80 In evaluating whether an accommodation would constitute
an undue hardship for the employer, the ADA instructs that the following
factors must be considered: (1) the accommodation’s nature and cost; (2)
the financial resources of the facility providing the accommodation and the
accommodation’s impact upon facility operations; (3) the employer’s
overall financial resources; and (4) the type of employer operation.81
Essentially, employers are not required to make an accommodation for a
disabled employee if it is beyond the employer’s means, financial or
otherwise.82 Specific to the scenario above, the construction company
should attempt to make a reasonable accommodation by allowing the
laborer to work only three days a week and attempting to find someone to
cover the other two days. If, however, that was not possible (for example,
the employer’s financial state was such that it could not pay both the new
laborer working five days a week and the original laborer working three
days a week), paying both employees could impose an undue hardship on
the construction company, who would then not be required to honor the
original laborer’s request. Whether an employer would experience a
legitimate undue hardship and truly could not afford to make any
reasonable accommodation for a disabled employee is ultimately a factsensitive, case-by-case inquiry.83
Furthermore, the ADA only protects employees to the extent that their
legal opioid use is not negatively affecting their job performance. Recall

79

42 U.S.C. § 12112(b)(5)(A).
42 U.S.C. § 12111(10)(A).
81
Id. at § 12111(10)(B).
82
Id. at § 12111(10)(A).
83
What Is Considered an “Undue Hardship” For a Reasonable Accommodation?,
ADA NAT’L NETWORK, https://adata.org/faq/what-considered-undue-hardship-reasonableaccommodation.
80
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that a “qualified individual” for ADA protection is one “who, with or
without reasonable accommodation, can perform the essential functions of
the employment position.”84 What constitutes “essential functions” of a job
is a fact-sensitive inquiry, but the ADA provides some deference to the
employer’s judgment, especially in the presence of a written job
description.85 For example, if an employee was legitimately no longer able
to perform the essential functions of their job because of their legallyprescribed opioid medication’s side effects, an employer could be within its
rights to terminate that employee. It is true that even the use of legallyprescribed opiates is not without risk; common side effects of opioids
include dizziness, nausea, vomiting, and physical dependence.86 These
risks could undoubtedly affect job performance in some employees.
Employers are not, however, entitled to complete deference in
determining whether a particular function is essential to a job. Aside from
an employer’s judgment about the essentiality of a job function, “[w]ritten
job descriptions prepared before interviewing applicants for the job; the
amount of time spent performing the function; consequences of not
requiring the incumbent to perform the function; terms of a collective
bargaining agreement; work experience of past incumbents; and/or current
work experience of incumbents in similar jobs”87 should also be
considered. Furthermore, all determinations of whether a function is
essential to a job have to take place on a case-by-case basis.88 Ultimately,
the EEOC explained that courts “are not intended to second guess an
employer’s business judgment” in the determination of what constitutes a
job’s essential functions.89 But to best protect the interests of their
qualified individual employee and protect themselves from legal liability,
employers still must evaluate the employee’s ability to perform the job on
an individualized, case-by-case basis, and should consider the other
aforementioned factors of what constitutes an essential job function.
Returning to the earlier hypothetical, if operating machinery is a clear
essential function of the employee’s job, but the employee cannot do so
because of the side effects of his legally-prescribed opioid medication, the
employer should document the inability of that employee to perform an
84

42 U.S.C. § 12111(8) (emphasis added).
See Lee, supra note 45, at 322–23.
86
See Ramsin Benyamin et al., Opioid Complications and Side Effects, PAIN
PHYSICIAN 11:S105 (2008), http://www.painphysicianjournal.com/current/pdf?article=OTg1
&journal=42.
87
29 C.F.R. § 1630.2(n)(3)(ii)–(vii) (2019).
88
Procedures for Providing Reasonable Accommodation for Individuals with
Disabilities, U.S. EQUAL EMP’T OPPORTUNITY COMM’N, https://www.eeoc.gov/eeoc/internal/
reasonable_accommodation.cfm (last visited Feb. 9, 2019).
89
See Lee, supra note 45, at 322–23.
85
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essential job function and could potentially fire the employee. Before
choosing to ultimately terminate that employee, however, the employer
must also consider potential reasonable accommodation alternatives, such
as restructuring the employee’s job responsibilities or reassigning the
employee to another vacant position, in order to maximize its insulation
from potential legal liability.90
In summary, employers must have a comprehensive understanding of
the protections extended to disabled employees under the ADA.
Employers are not, however, without recourse if the employee cannot
perform the essential functions of their job, even with a reasonable
accommodation, or if such reasonable accommodation would cause an
undue hardship to the employer.91
IV. THE NEED TO EXERCISE CAUTION IN DRAFTING DRUG POLICIES
Now armed with a greater understanding of the ADA as it pertains to
employment discrimination in the opioid context, this section emphasizes
that employers (and their lawyers) have to exercise caution and flexibility
in drafting and revising their workplace drug policies in order to avoid
legal exposure arising out of an employee’s opioid use. It will first
describe how employers must utilize care and precision when labeling
themselves as a “drug-free workplace,” so as not to punish employees’
legal opiate use in violation of the ADA. This section will then utilize case
law to demonstrate how failure to use such care has resulted in legal action
and subsequent liability against employers. Finally, it will also discuss
how drug testing and medical inquiry sections of employer drug policies
also need to be drafted with precision in order to avoid violating
employees’ ADA-protected rights and prevent legal exposure for
employers.
A. An Introduction to the “Drug-Free Workplace” Label
As Part IV.B. will illustrate, in light of the current opioid epidemic,
employers might be inclined to take action against their opiate-using
employees, even when the opiates are legally prescribed, to avoid potential
workplace problems. One method they might consider employing is a
“drug-free workplace” policy. A “drug-free workplace” sounds good in
theory, but employers must be wary of it in practice. Employers have been
subject to lawsuits and subsequent liability because they have made
adverse employment decisions against employees engaged in legal drug use
in the name of their “drug-free workplace” policies.
90
91

See 42 U.S.C. § 12111(9)(B) (2018).
Id. at § 12111(8).

CAMPISI-FORMATTED (DO NOT DELETE)

2019]

11/15/2019 7:25 PM

COMMENT

573

The “drug-free workplace” label is utilized by the federal government
in certain contexts92 and is encouraged by multiple states.93 The Federal
Drug-Free Workplace Act was passed by Congress in 1988 and stipulates
that federal contractors and federal grant recipients must provide a drugfree workplace by engaging in various steps, including “publishing a
statement notifying employees that the unlawful manufacture, distribution,
dispensation, possession, or use of a controlled substance is prohibited in
the grantee’s workplace and specifying the actions that will be taken
against employees for violations of the prohibition.”94 Multiple state
legislatures have cited their intent to promote drug-free workplaces so that
employers “may be afforded the opportunity to maximize their levels of
productivity, enhance their competitive positions in the marketplace, and
reach their desired levels of success without experiencing the costs, delays,
and tragedies associated with work-related accidents resulting from drug or
alcohol abuse by employees.”95 In fact, state legislatures are providing
incentives to employers to enact drug-free workplace policies, including
offering reductions in employers’ worker’s compensation premiums 96 or, as
in the federal Drug-Free Workplace Act, conditioning state grants and
contracts on the grantee employer having a drug-free workplace policy
barring illicit drugs from the workplace.97
The main issue with drug-free workplace policies is that employers
must be wary of the fact that their prohibitions may, inadvertently or
otherwise, extend to legally-prescribed drugs. The federal Drug-Free
Workplace Act and state analogs specify that they apply only to unlawful
or illegal drug use or drug-related activity. If not drafted carefully, drugfree workplace policies can lead to unwarranted discrimination against
individuals who can still safely and capably perform their jobs while taking
legally-prescribed drugs.98
Moreover, “the use of any particular
prescription drug, despite its side-effect warnings, is generally a poor
indicator of employee risk” by itself.99 Essentially, employers should not
assume that employees might pose a potential risk of problems arising in

92

See Drug-Free Workplace Act, 41 U.S.C. § 8101(a)(5) (2018).
U.S. DEP’T OF LABOR, 50 STATE SURVEY: DRUG-FREE WORKPLACE PROGRAMS (Sept.
1, 2009), http://www.lexisnexis.com/documents/pdf/20090930094905_large.pdf. See, e.g.,
FLA. STAT. ANN. § 112.0455; IOWA CODE § 730.5; OHIO ADMIN. CODE § 4123-17-58.
94
41 U.S.C.S. § 8102(a)(1)(A); 41 U.S.C.S. § 8103(a)(1)(A) (emphasis added).
95
ARK. CODE ANN. § 11-14-101. See also GA. CODE ANN. § 34-9-410; TENN. CODE
ANN. § 50-9-101.
96
ALA. CODE § 25-5-332; GA CODE ANN. § 34-9-412; IDAHO CODE § 72-1716.
97
30 ILL. COMP. STAT. ANN. 580/3; S.C. CODE. ANN. § 44-107-30; VA. CODE ANN. §
2.2-4312.
98
See Lee, supra note 45, at 337–38.
99
Id. at 338.
93
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the workplace on the basis of their legal opiate use.
It is critical that employers realize that they can easily insulate
themselves from legal liability and remain compliant with the ADA by
prohibiting only illegal drug use and activity in their drug-free workplace
policies. If employers have concerns about an employee’s use of legallyprescribed opiate medications negatively affecting their ability to
adequately perform their particular job, employers must take action after a
legitimate individualized evaluation, rather than relying solely upon a
blanket drug-free workplace policy.100
B. Case Law Illustrations of Why Employers Should Not Enact
Blanket Drug-Free Workplace Policies
Case law is instructive in understanding the significance of the
liability risks associated with drug-free workplace policies and how to
avoid them. The following cases will explain various circumstances in
which blind adherence to drug-free workplace policies has led to liability
exposure for employers and reinforce the need to ensure that such policies
make the legally necessary accommodations for an employee’s legal opioid
use.
1. Huffman v. Turner Industries Group, LLC
Huffman v. Turner Industries Group, LLC outlines a set of
circumstances in which an employer took adverse action against an
employee taking a legally-prescribed opioid medication because of the
employer’s blanket drug-free workplace policy. The employer incurred
significant legal fees and costs, while exposing itself to potential liability,
by blindly enforcing its policy prohibiting all opioids. The employer failed
to distinguish between legal and illegal drug use and acted on the blanket
premise that even legal prescription drug use prevented the employee from
performing his job, instead of conducting an individualized assessment of
the employee’s ability to capably perform his job. This case serves as a
warning to employers taking adverse action against employees in the name
of drug-free workplace policies instead of the employee’s work product.
In 1986, Henry Huffman, a welder, lost part of his hand in a welding
accident, and he took hydrocodone—an opioid pain medication—and
Xanax—a benzodiazepine—to manage his persistent chronic pain in the
aftermath.101 Between 2005 and 2011, Huffman had been intermittently
hired by Defendant Turner Industries Group (Turner) to work part-time as a

100
101

2013).

Id. at 338–39.
Huffman v. Turner Indus. Grp., LLC, 2013 U.S. Dist. LEXIS 71842, at *2 (E.D. La.
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welder on various occasions.102 In September 2011, Huffman was offered a
full-time job with Turner, contingent upon his successful completion of a
drug screening and a physical examination with Turner’s contracted
physician’s assistant.103 When Huffman told the physician’s assistant that
he took hydrocodone—an opiate—three to four times a day, he was
informed that such use was a violation of Turner’s “Drug, Alcohol, and
Contraband Policy,” which required that “employees who work in safetysensitive positions, such as that of a welder, not take narcotic pain
medications or benzodiazepines [anxiety medications] during working
hours or within eight hours of reporting to work.”104 Although Huffman
received a medical release from his physician stating that he required his
pain pills three to four times daily, he was told by Turner representatives
that he would still need to conform to their narcotic-free policy in order to
work as a welder and ultimately was not hired.105 Subsequently, Huffman
brought suit against Turner after receiving a right-to-sue letter from the
Equal Employment Opportunity Commission.106
Huffman alleged that he was not hired for full-time employment by
Turner because he had a record of physical impairment and/or was
regarded by Turner as having such impairment stemming from what he told
the physician’s assistant about his legal opioid use—and thus was
discriminated against on the basis of his disability.107 Huffman contended
that the factual record “‘unequivocally establishe[d]’ that Turner did not
base its employment decision on the kind of individualized and factintensive assessment envisioned by the ADA, but on a ‘blanket “zerotolerance” policy,’ [assuming] that ‘any person who takes prescription
narcotics, benzodiazepines, or muscle relaxers is too impaired to safely
perform jobs at Turner.’”108 Turner filed a motion for summary
judgment109 and maintained that Huffman could not establish a prima facie
case of discrimination because he could not establish that the decision not
to hire him was based on a record of disability or because Turner regarded
him as disabled.110 Further, Turner argued that even if Huffman could
establish a prima facie case, its drug policy served as an affirmative defense

102

Id.
Id.
104
Id.
105
Id. at *6.
106
Id. at *5–7.
107
Huffman, 2013 U.S Dist. LEXIS 71842, at *37–38. See also 29 C.F.R. §
1630.2(g)(1)(ii)–(iii) (2019).
108
Huffman, 2013 U.S. Dist. LEXIS 71842, at *28.
109
Id. at *2.
110
Id. at *23–24.
103
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because it “was both job-related and justified by business necessity.”111
Turner admitted that although the side effects of opioid medications, such
as drowsiness or dizziness, do not present themselves in everyone who
takes them, “the possibility of their occurrence is always present and
inherently dangerous when an individual performs a safety-sensitive task
such as welding.”112 The United States District Court for the Eastern
District of Louisiana denied Turner’s motion for summary judgment. 113
The court first established that Huffman satisfied the ADA’s definition of
disability because he had a record of disability and because Turner
regarded him as disabled.114 The court further found that Turner failed to
hire Hoffman because of the opioid medication he used to manage his
disability, thereby constituting sufficient evidence of a prima facie case of
discrimination to defeat summary judgment.115 The court next denied
Turner summary judgment on its affirmative defense of business
necessity.116 The court noted:
Plaintiff presents ample evidence that he performed the job of
Welder for six years between 2005 and 2011 without incident,
and, in fact, Turner notes that the ‘the only thing that changed
between late 2005 when Plaintiff was first hired, and September
16, 2011, when [he] was denied employment,’ was Plaintiff’s
disclosure of his use of hydrocodone and Xanax during work
hours.117
Moreover, Huffman had produced a doctor’s evaluation stating that he did
not experience any of the potential side effects of his medications.118
Turner’s blanket drug policy, for all intents and purposes, made the
company a drug-free workplace. Turner understandably wanted to promote
a safe environment, especially given the nature of some of the work
conducted, such as welding. In fact, Turner argued that the policy was
written in response to some of its employees being “involved in industrial
accidents at client job sites that were allegedly attributable to work-time
use of narcotic pain medication by employees working in safety-sensitive
positions.”119
The side effects of legally-prescribed opiates are certainly real and can
justifiably make employers nervous—especially those with employees
111
112
113
114
115
116
117
118
119

Id. at *25.
Id. at *26.
Id. at *23.
Huffman, 2013 U.S Dist. LEXIS 71842, at *39.
Id. at *39.
Id. at *52.
Id. at *40 (emphasis in original).
Id. at *50.
Id. at *2.
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working in safety-sensitive positions. Nonetheless, Huffman illustrates that
blanket drug policies likely are an over-inclusive and unacceptable method
of dealing with legal opioid use, and employers must realize that they can
reach the same goals by simply conducting individualized assessments.
Even from a pure financial standpoint, the extra time, effort, and cost to an
employer of conducting individualized assessments is a worthwhile
investment to avoid the very real possibility of much larger litigation costs
and potential legal liability. That type of legal exposure can lead to severe
consequences for employers, as further evidenced in the next section.
2. Stewart v. Snohomish County Public Utilities District No. 1
Stewart v. Snohomish County Public Utilities District No. 1 also
outlines the legal risk to employers of having a drug-free workplace policy
that bans not only illicit drug use, but categorically prohibits all drug use,
including the use of legally-prescribed medications. This case also
involves an employer who made a decision to terminate an employee for
failing to adhere to its drug-free workplace policy without conducting an
individualized assessment of the employee’s ability to perform her job.
The ultimate outcome of this case reveals just how serious and expensive
such a practice can be for employers.
In Stewart, Plaintiff Stewart was a customer service representative of
Defendant Snohomish County Public Utilities, an employer within the
meaning of the Washington Law Against Discrimination, for over twenty
years.120 Unfortunately, Stewart suffered from “chronic and debilitating”
migraines.121 While she would attempt to treat her migraines with nonnarcotic medications, she also had to go to her doctor for injections of
Dilaudid (hydromorphone)—an opiate—when the migraines would not
subside.122 Stewart acquired intermittent medical leave under the Family
and Medical Leave Act that allowed her to leave work for a few hours at a
time to receive her injections, but her supervisors consistently gave her a
difficult time for her absenteeism.123 Defendant had a “Fitness for Duty”
policy prohibiting all employees from working under the influence of drugs
and alcohol, but, critically, the policy did not exempt employees taking
legally-prescribed medications.124

120

Stewart v. Snohomish Cty. Pub. Utils. Dist. No. 1, 262 F. Supp. 3d 1089, 1093
(W.D. Wash. 2017).
121
Id. at 1094.
122
Id.
123
Id. at 1095.
124
Id. at 1094.
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Stewart became upset after being confronted by a supervisor about her
absence upon returning from an injection in October 2014.125 Her
supervisors thought she was showing signs of impairment at work and
drove her to be drug tested, informing her that she would be put on
administrative leave while they “investigated her.”126 The drug test came
back positive and, unsurprisingly, showed the presence of
hydromorphone.127 In order to be permitted to return to work, Stewart
signed a “Return to Work Agreement,” stating that she would be fired if
she came to work while impaired.128 In April 2015, a few months after
returning to work, Stewart had a similar experience to what had transpired
in October 2014.129 After being driven to another drug test in which she,
again, tested positive for hydromorphone, Stewart was terminated for
violating the Fitness for Duty Policy and Return to Work Agreement by
“coming to work while impaired.”130
While the record made it difficult to ascertain whether Stewart was
actually impaired on the days of the October 2014 and April 2015
incidents, or simply upset by the way she was being treated by her
employer, the court found that Defendant “ha[d] not shown that any
impairment prevented Stewart from properly performing her job [on either]
day.”131 As a result, the court determined that Stewart had a disability that
could have been reasonably accommodated by Defendant, but Defendant
“chose to address Stewart’s symptoms through a disciplinary process rather
than an interactive one aimed at finding a reasonable accommodation that
would allow Stewart to work and seek treatment for her disability.”132 The
court further found that reasonable accommodations could have easily been
made and that Defendant “could have treated her as an employee with a
medical condition, rather than a drug abuser.”133 Because Defendant chose
to terminate Plaintiff based upon violations of its blanket drug prohibition
policy—which made no exceptions for legal drug use—instead of making
reasonable accommodation efforts, the court awarded Plaintiff over $1.8
million in damages.134
Stewart is a cautionary tale that warns employers, in drafting their
drug policies, against adopting a policy that blindly imposes blanket
125
126
127
128
129
130
131
132
133
134

See id. at 1096.
See Stewart, 262 F. Supp. 3d at 1097.
See id.
See id. at 1098–99.
See id. at 1100–01.
See id. at 1101–02.
Id. at 1097, 1101.
See Stewart, 262 F. Supp. 3d at 1105.
Id. at 1106.
See id. at 1113.
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prohibitions on all drug use.135 Whether the “drug-free workplace” label is
specifically used in the language of the policy or not, employers (and their
lawyers) must recognize that it is illegal to create drug-free workplaces
that, in effect, do not accommodate the legal use of opiate medications.
C. Employers Must Carefully Craft the Drug Testing and Medical
Inquiry Components of their Drug Policies to Protect Themselves
from Liability
Employers have the right to drug test and make medical inquiries of
job applicants and employees, but only at specific times and under specific
circumstances.136 Employers are permitted to require their job applicants
and employees to undergo illegal drug testing, as well as make employment
decisions as a result of those tests.137 In order to best protect themselves
from liability and to give future or current employees reasonable notice that
consequences may follow for certain actions, an employer’s drug policy
should be explicit in describing when and under what circumstances the
employer may require a drug test or conduct a drug-related medical
inquiry. As a matter of best practices, the policy should also clearly
describe what consequences an employee can expect if they have a positive
drug test.
Employers can also make medical inquiries of current or prospective
employees in order to ascertain their ability to do the job, but must be wary
of the various ADA guidelines in place to ensure that such inquiries are not
being used to wrongfully discriminate against employees. These ADA
guidelines “reflect Congress’s intent to protect the rights of applicants and
employees to be assessed on merit alone, while protecting the rights of
employers to ensure that individuals in the workplace can efficiently
perform the essential functions of their jobs.”138
Notably, the ADA guidelines distinguish permitted medical inquiries
on the basis of whether the qualified individual is a job applicant, has
already received an offer of employment, or is a current employee.139 Prior
to making an offer of employment to a job applicant, employers cannot
“conduct a medical examination or make inquiries of a job applicant as to
135

See generally Stewart, 262 F. Supp. 3d at 1089.
See 42 U.S.C. § 12114(d) (2018) (explaining that a test for illegal drugs shall not be
considered a medical examination); 42 U.S.C. §12112(d) (setting forth the limited
circumstances in which employers can make a medical examination or inquiry).
137
See 42 U.S.C. §§ 12114(d)(1)–(2).
138
See generally Enforcement Guidance: Disability-Related Inquiries and Medical
Examinations of Employees Under the Americans with Disabilities Act (ADA), U.S. EQUAL
EMP’T OPPORTUNITY COMM’N (July 27, 2000), https://www.eeoc.gov/policy/docs/guidanceinquiries.html#N_5_.
139
See 42 U.S.C. § 12112(d)(2)–(4).
136
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whether such applicant is an individual with a disability or as to the nature
or severity of such disability,”140 but they can ask about “the ability of an
applicant to perform job-related functions.”141
Once an offer of
employment has been made, employers can condition that offer on
successful completion of a medical examination, as long as that is the
standard procedure for all entering employees.142 Once a person is
officially an employee, employers may conduct voluntary medical
examinations and inquire into the ability of the employee to perform jobrelated functions.143 Employers cannot require a current employee to
undergo a medical examination and “shall not make inquiries of an
employee as to whether such employee is an individual with a disability or
as to the nature or severity of the disability, unless such examination or
inquiry is shown to be job-related and consistent with business
necessity.”144
Despite these ADA guidelines, case law demonstrates that sometimes
employers’ drug policies or medical inquiries are overly broad and
intrusive into an employee’s legal drug use, thereby leaving that employer
susceptible to legal claims.
1. Harrison v. Benchmark Electrics of Huntsville, Inc. and
Medical Inquiries of Job Applicants
In Harrison v. Benchmark Elecs. Huntsville, Inc., Plaintiff, a
temporary worker for the Defendant, applied for a full-time position at the
request of his supervisor.145 After testing positive for barbiturates during
the application process, his supervisor called him into his office to speak
over the phone with a Medical Review Officer.146 The supervisor did not
leave the room, however, when Plaintiff answered the Medical Review
Officer’s questions regarding his private medical information, such as the
fact that he had suffered from epilepsy since he was an infant, took the
barbiturates to control the condition, and revealed his dosage amounts.147
The supervisor subsequently told the human resources department not to
extend a job offer to the Plaintiff.148 The Eleventh Circuit reversed the
District Court’s grant of summary judgment to the Defendant, finding that
the ADA prohibits medical inquiries “as to whether such applicant is an
140
141
142
143
144
145
146
147
148

42 U.S.C. § 12112(d)(2)(A).
Id. at § 12112(d)(2)(B).
See id. at § 12112(d)(3)(A).
See id. at § 12112(d)(4)(B).
See id. at § 12112 (d)(4)(A).
See 593 F.3d 1206, 1209 (11th Cir. 2010).
See id. at 1210.
See id.
See id.
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individual with a disability or as to the nature or severity of such
disability”149 before an offer of employment is made. The Eleventh Circuit
further held that “a reasonable jury could infer that the supervisor’s
presence in the room was an intentional attempt likely to elicit information
about a disability in violation of the ADA’s prohibition against preemployment medical inquiries.”150 Thus, if Plaintiff had already been an
employee at the time of his positive drug test, the employer could have
undertaken a medical inquiry without fear of liability as long as it was jobrelated and consistent with business necessity. Because the Plaintiff was
still only a job applicant, however, the Defendant was not within its legal
rights to attempt any inquiry into the Plaintiff’s disability status.
2. Roe v. Cheyenne Mountain Conference Resort and Medical
Inquiries of Current Employees
In Roe v. Cheyenne Mountain Conference Resort, Defendant
Cheyenne Mountain Conference Resort developed a new Drug and Alcohol
Testing Policy which Plaintiff, a current employee, refused to consent to,
citing its requirements as unreasonable and intrusive.151 Plaintiff brought
the action to enjoin its implementation.152 The employer’s drug policy at
issue read: “[e]mployees must report without qualification, all drugs
present within their body system. Further, they must remain free of drugs
while on the job . . . . Additionally, prescribed drugs may be used only to
the extent that they have been reported and approved by an employee
supervisor . . . .”153 The United States District Court for the District of
Colorado held that this prescription drug disclosure provision violated the
ADA, a decision that was upheld by the Tenth Circuit Court of Appeals
even though other aspects of the case were reversed and remanded.154 The
District Court found that the prescription drug disclosure provision at issue
violated section 12112(d)(4)(A) of the ADA,155 which provides that an
employer cannot require medical examinations or make inquiries of an
employee’s disability “unless such examination or inquiry is shown to be
job-related and consistent with business necessity.”156 Since the Defendant
failed to make any such showing, the District Court held, and the Tenth
Circuit affirmed, that the drug policy violated the “plain language” of the

149
150
151
152
153
154
155
156

42 U.S.C. § 12112(d)(2)(A).
Harrison, 593 F.3d at 1216.
See Roe v. Cheyenne Mt. Conf. Resort, 124 F.3d 1221, 1226 (10th Cir. 1997).
See id.
Id. (emphasis removed).
See id. at 1231.
See Roe v. Cheyenne Mt. Conf. Resort, 920 F. Supp. 1153, 1155 (D. Colo. 1996).
42 U.S.C. § 12112(d)(4)(A) (2018).
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ADA.157 Thus, the employer left itself open to potential liability by
requiring in its policy that employees report all drug use without showing
that such inquiry was job-related and consistent with business necessity, in
direct violation of the ADA’s protections for legal drug users.
D. Conclusions on Drug Policies
While many employers have existing policies regarding drug use in
the workplace, it is imperative that employers understand that they: (1)
cannot impose a blanket “drug-free workplace” policy without exposing
themselves to significant legal ramifications; and (2) must differentiate
between illegal drug use, which is not permitted, and legal drug use, which
may be permitted. Including prohibitions on legal drug use in drug policies
and taking adverse action against an employee or job applicant because of
such use leaves the employer open to unnecessary liability.
As
demonstrated by the $1.8 million award to the plaintiff in Stewart,158 that
liability can be quite costly.
Further, employers should ensure that any drug testing and medical
inquiry provisions of their drug policies are compliant with the ADA’s
various guidelines about when such testing and inquiries are permitted. In
so doing, employers will protect the rights of their employees, who deserve
to be free from worry of disability status discrimination and to be judged on
the basis of the merits of their job performance. Simultaneously,
employers will be reducing their own legal exposure by ensuring that any
adverse action that is taken against an employee in accordance with their
drug policies will be compliant with ADA regulations.
V. RECOMMENDATIONS FOR SUPPORTING EMPLOYEES
Part III explained that employers have a legal obligation to remain
compliant with federal and state anti-discrimination laws and ensure that
they do not wrongfully discriminate against job applicants or employees
engaged in legal prescription opiate use.159 But, as a policy matter,
employers’ roles can and should expand far beyond simply ensuring their
compliance with anti-discrimination employment regulations. In fact,
employers can take proactive steps towards combatting the opioid epidemic
to achieve a twofold purpose: providing valuable assistance to employees
and protecting employers from legal liability by offering their employees
support before problems related to opioid use, or even abuse, arise.
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Roe, 920 F. Supp. at 1155.
Stewart v. Snohomish Cty. Pub. Utils. Dist. No. 1, 262 F. Supp. 3d 1089, 1113
(W.D. Wash. 2017).
159
See Parts III.A., Part IV.B.
158
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Fortunately, many employers have shown a willingness to take a more
active role in providing assistance to their employees during the opioid
crisis. According to a National Safety Council survey about the effect of
prescription drugs upon employers, 70% percent of employers said they
would like to help employees struggling with prescription drug misuse or
abuse, and 48% percent responded that they would return the employee to
their position after appropriate treatment.160 Such help is critical, according
to Deborah Hersman, the president and CEO of the National Safety
Council, because “[r]esearch indicates that those struggling with substance
abuse have better sustained recovery rates if their employers help them to
receive treatment and monitor their recovery, than if treatment is initiated
by family or friends[.]”161
A. Employers May Be Able to Negotiate Alternative Pain Treatment
Coverage with Health Insurance Companies
Opioids are commonly prescribed as pain medications. “In recent
years, there has been a dramatic increase in the acceptance and use of
prescription opioids for the treatment of chronic, non-cancer pain, such as
back pain or osteoarthritis, despite serious risks and the lack of evidence
about their long-term effectiveness.”162 In fact, “[t]he amount of opioids
prescribed and sold in the United States has quadrupled since 1999, but the
overall amount of pain reported by Americans hasn’t changed.”163 Since
health care providers started prescribing more opioids for pain management
in the late 1990s,164 the risks of these medications have manifested more so
than the rewards. Unfortunately, as many as one in four patients receiving
legally-prescribed opioid therapy struggle with addiction.165 Thus, while
the availability of opioid pain medications remains an important option for
patients—in fact, for some patients, a necessary and indispensable one166—
160

See 2017 NSC Report, supra note 33, at 16.
Stephen Miller, As Opioid Epidemic Rages, Worksite Policies Overlook Prescribed
Drugs, SOC’Y FOR HUMAN RES. MGMT. (Mar. 17, 2017), https://www.shrm.org/resourcesand
tools/hr-topics/benefits/pages/workplace-rx-drug-policies.aspx.
162
Prescription Opioids, CTR. FOR DISEASE CONTROL AND PREVENTION (Aug. 29, 2017),
https://www.cdc.gov/drugoverdose/opioids/prescribed.html.
163
CDC Guideline for Prescribing Opioids for Chronic Pain, CTR. FOR DISEASE
CONTROL AND PREVENTION https://www.cdc.gov/drugoverdose/pdf/guidelines_at-a-glancea.pdf (last visited Sept. 29, 2019).
164
Opioid Overdose Crisis, NAT’L INST. ON DRUG ABUSE (Mar. 2008),
https://www.drugabuse.gov/drugs-abuse/opioids/opioid-overdose-crisis.
165
Prescription Opioids - Addiction and Overdose, CTR. FOR DISEASE CONTROL AND
PREVENTION (Aug. 29, 2017), https://www.cdc.gov/drugoverdose/opioids/prescribed.html.
166
See, e.g., Will Stone, Patients with Chronic Pain Feel Caught in an OpioidPrescribing Debate, KAISER HEALTH NEWS (Aug. 1, 2018), https://khn.org/news/patientswith-chronic-pain-feel-caught-in-an-opioid-prescribing-debate/.
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health care providers have also been encouraged to start evaluating
alternative pain treatment options.167 These alternative pain treatment
options can include, among others, acupuncture, physical therapy,
cognitive behavioral therapy, yoga, and chiropractic treatment.168
State Medicaid agencies have already made an effort to cover
alternative pain treatments that can be used instead of opioids when
appropriate.169 As of the most recent data from the Henry J. Kaiser Family
Foundation, which tracks Medicaid benefits offered by the states, all but six
states reimburse providers for at least one category of alternative pain
treatment, including physical therapy, occupational therapy, and
chiropractic services.170 In a 2016 survey conducted by the National
Academy for State Health Policy, twelve states said that their Medicaid
agency “implemented specific policies or programs to encourage or require
alternative pain management strategies in lieu of opioids for acute or
chronic non-cancer pain.”171
Similarly, private employers, individually or in conjunction with other
private employers, may be able to negotiate with their health insurers for
pain management treatments that could serve as an alternative to opioids.
Such treatments have shown efficacy in reducing pain172 without the risk of
tolerance or addiction presented by opioids. These treatments provide
patients with safer pain management alternatives, thereby reducing the risk
of impairment occurring at work and potential conflicts between the
employer and employee arising from such impairments. By providing
employees with the ability to utilize alternative pain treatments in cases
where their conditions are not so severe as to necessitate the use of opioids,
employers can play an important role in reducing the number of employees
who turn to opioids for pain management (and the corresponding risk of
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See generally Deborah Dowell, Tamara M. Haegerich, & Roger Chou, CDC
Guideline for Prescribing Opioids for Chronic Pain – United States, 2016, CTR. FOR
DISEASE CONTROL AND PREVENTION MORBIDITY AND MORTALITY WEEKLY REPORT 16 (Mar.
18, 2016), https://www.cdc.gov/mmwr/volumes/65/rr/pdfs/rr6501e1.pdf.
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Dean Drosnes, Chronic Pain Management: There Are Alternatives to Opioids,
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addiction), thereby limiting the negative impacts of opioid use in the
workplace. In doing so, employers would offer a valuable benefit to their
employees, and at the same time, lower the risk of a potential liability
arising from opioid use in the workplace.
B. Employers Must Comply with the Family and Medical Leave Act
Regulations as They Relate to Substance Use Disorder.
The Family and Medical Leave Act (the “FMLA”) allows eligible
employees of a covered employer to take job-protected leave (paid or
unpaid depending on the circumstances) for up to twelve weeks per year
“because the employee is needed to care for a family member with a
serious health condition [or] because the employee’s own serious health
condition makes the employee unable to perform the functions of his or her
job . . . .”173 Generally, an eligible employee “has been employed for a
total of at least [twelve] months by the employer on the date on which any
FMLA leave is to commence,”174 and covered employers are those
engaging in commerce who employ fifty or more employees.175
Substance use disorder can qualify as a serious health condition,
providing that it requires inpatient care or continuing treatment by a
healthcare provider.176 An employee can only take FMLA leave for
continuing treatment by a healthcare provider, however, upon health care
provider referral.177 Employers cannot take adverse action against an
employee taking FMLA leave to care for a family member receiving
substance use disorder treatment.178 Upon completion of FMLA leave, an
employee is entitled to return to either the same position or an equivalent
position.179
Because employees taking leave to care for a family member suffering
from substance use disorder are fully protected against any adverse
employment actions by the FMLA,180 it is prudent for employers to offer
their support for their caregiver employees by quickly and amiably granting
FMLA leave when it is requested. By displaying understanding and
keeping the employee’s job or an equivalent position ready for their return,
employers can offer comfort to employees during troubling times and
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29 C.F.R. § 825.100(a) (2019).
Id. at § 825.102.
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Id. at § 825.104(a).
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Id. at § 825.119(a). For further explanation of the intricacies of what constitutes
“continuing treatment by a healthcare provider,” see 29 C.F.R. §825.115.
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Id. at § 825.119(a).
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Id. at § 825.119(b).
179
29 C.F.R. § 825.100(c).
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Id. at § 825.119(b).
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prevent exposure to future liability at the same time.
Employees can take leave to receive treatment for substance use
disorder, but an employee’s absence from work resulting from that
employee’s use of a substance such as opiates is not covered under the
FMLA.181 Put more simply, employers can grant an employee FMLA
leave to obtain substance use disorder treatment. But, if an employee does
not show up at work one day because of their substance use, the employee
cannot then go back and ask for that day they missed to be covered under
FMLA leave.
Furthermore, employers cannot take adverse action against an
employee for taking FMLA leave to obtain substance use disorder
treatment. That does not, however, mean that an employee is protected
against all adverse actions stemming from substance use. If an employer
has an “established policy, applied in a non-discriminatory manner that has
been communicated to all employees, that provides under certain
circumstances an employee may be terminated for substance abuse,
pursuant to that policy the employee may be terminated whether or not the
employee is presently taking FMLA leave.”182 In other terms, if an
employer has a clear policy that stipulates that employees may be
terminated for substance use disorder under certain circumstances, and this
policy applies to and is communicated to all employees, the fact that the
employee is now on FMLA leave seeking treatment for substance use
disorder does not prevent the employer from taking adverse action. Such a
policy would still, however, remain subject to aforementioned ADA
requirements. Employers cannot take adverse action against an employee
for their legal drug use, so they must ensure that this policy permitting
termination of employees for “substance abuse” would only apply to an
employee’s current, illegal drug use.
C. Employers May Promote a Work Environment Where Employees
Know About and are Not Afraid to Seek Out Their Company’s
Employee Assistance Program.
“An employee assistance program is a work-based intervention
program designed to assist employees in resolving personal problems that
may be adversely affecting the employee’s performance.”183 Larger
employers will likely have an employee assistance program for employees
to utilize. Over 97% of companies with more than 5,000 employees, 80%
181

Id. at § 825.119(a).
Id. at § 825.119(b).
183
General: What is an Employee Assistance Program (EAP)?, SOC’Y FOR HUM. RES.
MGMT. https://www.shrm.org/resourcesandtools/tools-and-samples/hr-qa/pages/whatisaneap
.aspx (last visited Sept. 29, 2019).
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of companies with 1,001 to 5,000 employees, and 75% of companies with
251 to 1,000 employees have employee assistance programs.184 An
employee assistance program can help an employee struggling with opiate
misuse or abuse by “offer[ing] counseling and referral services;
conduct[ing] substance abuse evaluations[,] connect[ing] an employee to a
qualified substance abuse professional . . . [and monitoring an] employee’s
participat[ing] in, and compliance with treatment as well as return-to-work
recommendations.”185
Employers with employee assistance programs should play a more
active role in promoting their services to employees. Despite the large
percentage of companies with employee assistance programs, the national
average of employees who utilize them is only 3%.186 Some employees
might not even know that employee assistance programs are available to
them.187 Employees have also expressed confidentiality concerns about
information getting back to employers.188 Therefore, employers can create
more productive workplaces by proactively encouraging their employees to
utilize employee assistance programs when necessary and assuring them
that those services are confidential in accordance with Health Insurance
Portability and Accountability Act of 1996 (HIPPA) regulations.189 Such a
policy allows employers to help employees nip a potential opioid abuse
problem in the bud and/or assist employees in obtaining the appropriate
treatment.
VI. CONCLUSION
As the U.S. confronts the opioid national public health emergency,
employers might find themselves navigating through some murky waters.
Employers should ensure that they have carefully-drafted drug policies that
both promote a productive work environment for their employees and
shield themselves from potential liability. Drug policies should specify,
and enforce, prohibitions on illegal drug use in the workplace. In the
context of legal drug use, however, adverse action against an employee
184
Frequently Asked Questions, INT’L EMP. ASSISTANCE PROF’L ASS’N,
http://www.eapassn.org/faqs (last visited Sept. 29, 2019).
185
How Employee Assistance Programs Can Address Opioid Painkiller Abuse and
Addiction, NAT’L SAFETY COUNCIL (2014), https://www.nsc.org/Portals/0/Documents/RxDr
ugOverdoseDocuments/RxKit/EMP-How-Employee-Assistance-Programs-can-AddressPainkiller-Abuse-and-Addiction.pdf [hereinafter 2014 NSC Report].
186
Id.
187
See Alia Hoyt, Why Hardly Anyone Uses Employee Assistance Programs, HOW
STUFF WORKS (Aug. 22, 2017), https://money.howstuffworks.com/why-hardly-anyone-usesemployee-assistance-programs.htm.
188
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189
See 2014 NSC Report, supra note 185.

CAMPISI-FORMATTED (DO NOT DELETE)

11/15/2019 7:25 PM

588

[Vol. 50:559

SETON HALL LAW REVIEW

must only be based on legitimate, objective individual assessments of the
employee’s inability to competently and safely perform the job (despite any
reasonable accommodations made) rather than reliance on rigid “drug-free
workplace” labels. Following these guidelines reduces the chances of a
lawsuit and minimizes, if not eliminates, legal liability should a disgruntled
employee or former employee still choose to bring suit.
Employers must ensure that their policies governing drug testing and
medical inquiries are consistent with the different set of rules that apply to
job applicants, those who have received a job offer, and current employees.
Those policies should not be overly broad or intrusive as applied to an
employee’s legal drug use. Finally, employers should seek to surpass mere
compliance with their drug policies and instead engage in proactive
strategies offering supports to their employees. Employers can take the
initiative to negotiate for alternative pain management coverage in their
offered health insurance plans and promote their employer assistance
programs, as well as execute their legal obligation to allow employees to
exercise their FMLA right to leave with compassion and understanding. In
doing so, employers can help to prevent opioid-related problems in the
workplace before they begin, can support and foster goodwill with their
employees, and further protect themselves from potential legal liability.

